Intellia Therapeutics Inc (NAS:NTLA)
$ 15.21 0.48 (3.26%) Market Cap: 1.55 Bil Enterprise Value: 992.63 Mil PE Ratio: 0 PB Ratio: 1.61 GF Score: 60/100

Intellia Therapeutics Inc at Barclays Global Healthcare Conference Transcript

Mar 12, 2019 / 07:20PM GMT
Release Date Price: $16.83 (+1.51%)
John M. Leonard
Intellia Therapeutics, Inc. - President, CEO & Director

Four minutes, just introducing company, giving you a quick overview of where are we and some of the things to bear in mind with respect to Intellia.

Forward-looking statement. In a nutshell, Intellia is a CRISPR/Cas9 gene editing company. What we're building at the organization is something we call a full spectrum genome editing company, I'll talk a little bit about that in the comments to come. But in a nutshell, that really reflects the work that we're doing in the in vivo gene editing side and our work to build world-class engineered cell therapy company as well. A key to thinking about us is that we're doing this work in a modular approach where we solve a variety of different problems, aggregate that technology and put ourselves in a position where we can play that out as we move to various product candidates and gain efficiencies in the process. In the short time that we've been a company in Cambridge, Massachusetts we've made a lot of progress, have very significant in vivo preclinical work that we've done. Some

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot